Vithas and MSD Join Forces to Train and Innovate in Oncology Matters

New agreement between the healthcare and pharmaceutical sectors. Vithas and MSD have launched an alliance with the main objective of “ contributing to the improvement of care and quality of life for patients with cancer ” and other pathologies, according to the company statement.

Within their commitment to innovation and health research, both companies have signed the agreement, with a minimum duration of two extendable years, coinciding with the launch of the Vithas Oncology Institute (IOV).

This center will be the hospital company’s main instrument for its development together with the Vithas Foundation, the Vithas PlazaSalud+ purchasing center and the group’s group of hospitals.

The framework agreement includes the collaboration of Vithas and MSD in carrying out joint training projects and programs, activities related to innovation, technological development and social promotion of health education in different therapeutic areas , including the oncology field.

Vithas has exceeded 700 million euros in turnover in 2023

Apart from the future Esplugues de Llobregat hospital, Vithas already has two medical centers in Lleida and Vilanova i la Geltrú (Barcelona) . All this offer and resources have led the healthcare group to exceed 700 million euros in turnover in 2023.

Vithas is owned by the parent company Goodgrower , created in 2007 by the Gallardo family, owners of Almirall. Since its creation in the mid-2000s, this division had already acquired some health centers, but it was in 2011 when Vithas began to be built as it is known today , after the purchase of 80% of the division that grouped Adeslas’ hospital offering. Segurcaixa. With this operation, Goodgrower acquired ten hospitals at once and worked side by side with Criteria Caixa in the hospital sector for almost a decade.

Currently, Goodgrower is chaired by Jorge Gallardo Piqué, part of the third generation of the family and brother of Carlos Gallardo, president of Almirall. The Gallardos have controlled 100% of Goodgrower since 2020 after purchasing the remaining 20% ​​from Criteria Caixa for 93 million euros .

The Vithas group is made up of twenty hospitals and 37 medical and care centers distributed throughout 14 provinces with more than 12,000 professionals in its lines. In addition, the group integrates the Vithas Foundation, Vithas Red Diagnóstica and the PlazaSalud+ purchasing center.

__

(Featured image by Ousa Chea via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us